TrialBritish journal of cancer2005

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.

A O'Donnell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.